Core Management Principles
Management of CCF utilizes a structured, four-pronged approach targeting inadequate cardiac output.
- Reduce cardiac work.
- Augment myocardial contractility.
- Improve cardiac performance via preload and afterload reduction.
- Identify and correct underlying structural or metabolic causes.
General Supportive Care
Environmental and Postural Interventions
- Restrict physical activities to lower metabolic demand.
- Treat exacerbating triggers including fever, obesity, and systemic infections.
- Correct anemia via packed red blood cell transfusion (10-20 mL/kg). Administer intravenous furosemide prior to transfusion.
- Nurse neonates in incubators with minimal handling.
- Maintain neutral thermal environment (36-37°C) minimizing caloric and circulatory expenditure.
- Prop infants at a 30° incline to pool edema fluid in dependent areas and reduce respiratory work.
- Provide 40-50% humidified oxygen for isolated pulmonary congestion.
- Avoid indiscriminate oxygen supplementation in left-to-right shunt lesions. Oxygen acts as a pulmonary vasodilator, inappropriately increasing pulmonary flow and worsening systemic hypoperfusion.
- Employ cautious sedation in highly restless or dyspneic patients.
Nutritional and Fluid Management
- Implement high-calorie feeding to counteract excessive metabolic demands and profound failure to thrive.
- Fortify formula caloric density. Limit fortification >24 kcal/oz if diarrhea or renal solute load issues manifest.
- Utilize continuous nocturnal nasogastric (NG) drip feeding. Overcomes extreme feeding fatigue, rapid respirations, and reduces gastroesophageal reflux.
- Prefer human breast milk as ideal low-sodium nutritional source.
- Avoid routine low-sodium infant formulas. Poorly tolerated and exacerbates diuretic-induced hyponatremia.
- Older children require general heart-healthy diets (low fat, low sugar).
Pharmacological Management
Preload Reduction (Diuretics)
Reduce circulating blood volume, relieve pulmonary edema, and lower ventricular filling pressures.
| Class | Agent | Mechanism/Clinical Notes | Dosage |
|---|---|---|---|
| Loop Diuretics | Furosemide | Inhibits Na/Cl reabsorption in loop of Henle. Rapid onset (20 min PO). Risk of contraction alkalosis, K+ depletion. Synergistic with ACE inhibitors. | IV: 1-2 mg/kg/dose. PO: 1-4 mg/kg/day divided 1-4 times. |
| Loop Diuretics | Bumetanide | Potent loop diuretic alternative. | IV/PO: 0.01-0.1 mg/kg/dose. |
| Thiazides | Chlorothiazide | Inhibits electrolyte reabsorption in distal tubule. Less potent than furosemide. | PO: 20-40 mg/kg/day divided twice or thrice. |
| Aldosterone Antagonists | Spironolactone | Promotes natriuresis and potassium retention. Blunts adverse cardiac fibrosis/remodeling. | PO: 1-3 mg/kg/day divided twice or thrice. |
Afterload Reduction (Vasodilators)
Inhibit inappropriate compensatory renin-angiotensin-aldosterone system (RAAS) activation. Reduces systemic vascular resistance, thereby decreasing ventricular afterload.
| Class | Agent | Mechanism/Clinical Notes | Dosage |
|---|---|---|---|
| ACE Inhibitors | Captopril | Blocks Angiotensin II production. Causes arterial/venous dilation. Monitor for acute kidney injury, dry cough, hypotension. Avoid in dehydration/neonates. | PO: 0.1-0.5 mg/kg/dose (Children). |
| ACE Inhibitors | Enalapril | Long-acting alternative to Captopril. | PO: 0.08-0.5 mg/kg/day divided q12-24h. |
| ARBs | Losartan | Utilized if ACE inhibitors induce persistent cough. | Titrate per clinical response. |
| ARNi | Sacubitril/Valsartan | Neprilysin inhibitor combined with ARB. Approved for >1 year age with systemic left ventricular systolic dysfunction (EF ⇐40%). | Dose depends on age/weight. |
| Direct Vasodilators | Sodium Nitroprusside | Acute care veno-arterial dilation. | IV: 0.5-8 µg/kg/min. |
Myocardial Contractility Augmentation (Inotropes)
Indicated for severe decompensation, low-output states, or cardiogenic shock.
| Class | Agent | Mechanism/Clinical Notes | Dosage |
|---|---|---|---|
| Cardiac Glycoside | Digoxin | Inhibits Na-K ATPase. Increases intracellular Ca2+. Enhances contractility, enhances vagal tone, lowers heart rate. Synergistic with ACEi. | PO Load: 25-60 µg/kg total. PO Maint: 2.5-15 µg/kg/day. |
| PDE-3 Inhibitor | Milrinone | Inodilator. Inhibits cAMP degradation. Increases contractility and causes peripheral vasodilation. Treats refractory low cardiac output. | IV: 0.25-1.0 µg/kg/min. Load 50 µg/kg. |
| Calcium Sensitizer | Levosimendan | Increases myocardial contractility without elevating intracellular calcium or oxygen demand. | IV Load: 6-12 µg/kg over 10 min. Maint: 0.05-0.2 µg/kg/min. |
| Catecholamines | Dobutamine / Dopamine | Acute ICU use. Increases cAMP via beta-adrenergic stimulation. Dopamine <5 µg causes renal vasodilation/natriuresis. | IV: 2-20 µg/kg/min. |
Beta-Adrenergic Blockers
- Counteract chronic maladaptive catecholamine surges.
- Improve symptoms and induce reverse remodeling in stable, chronic CCF.
- Contraindicated during acute decompensation requiring intravenous inotropes.
- Carvedilol: Non-selective alpha/beta blocker with free-radical scavenging properties. Preferred agent. Start low dose (0.08-0.4 mg/kg/day) and titrate slowly (max 1.0 mg/kg/day).
- Metoprolol: Selective beta-1 adrenergic receptor antagonist.
Novel Therapeutics
- Ivabradine: Selectively inhibits the If (“funny”) current in the sinoatrial node. Lowers resting heart rate without depressing myocardial contractility.
- SGLT2 Inhibitors (e.g., Dapagliflozin, Empagliflozin): Block proximal tubule glucose reabsorption. Induce profound natriuresis/glucosuria. Emerging role in refractory HFpEF/HFrEF.
Acute Heart Failure: Hemodynamic Profiling
Rapidly categorize acute CCF presentations by evaluating venous congestion (“wet” vs “dry”) and systemic perfusion (“cold” vs “warm”) to guide targeted interventions.
| Profile | Clinical Status | Immediate Management Strategy | Prognosis |
|---|---|---|---|
| Warm-Dry | Adequate perfusion, no congestion. | Optimize chronic oral medications. | Lowest mortality. |
| Warm-Wet | Adequate perfusion, significant congestion. | Administer diuretics. Titrate cautiously to avoid precipitating low output. | Favorable trajectory. |
| Cold-Dry | Poor perfusion, no congestion. | Avoid diuretics. Trial careful volume expansion. | High risk. |
| Cold-Wet | Poor perfusion, severe congestion. | Highest mortality risk. Early initiation of IV inotropes. Evaluate rapidly for mechanical circulatory support. | Threefold higher mortality. |
Correcting Underlying Causes
- Medical management acts as temporary stabilization for surgically amenable lesions.
- Definitive cure requires rapid identification and correction of structural pathology.
- Provide prostaglandin E1 infusion (0.05-0.1 µg/kg/min) for ductal-dependent lesions (e.g., coarctation, HLHS).
- Treat tachycardia-induced cardiomyopathy with cardioversion or antiarrhythmics.
- Correct severe hypocalcemia, hypoglycemia, or upper airway obstructions immediately.
- Perform surgical anomalous left coronary artery (ALCAPA) reimplantation to halt irreversible myocardial ischemia.
Advanced Interventions and Surgical Care
Electrophysiology Interventions
- Implantable Cardioverter-Defibrillator (ICD): Indicated for survivors of cardiac arrest or primary prevention in high-risk dilated/hypertrophic cardiomyopathy phenotypes.
- Cardiac Resynchronization Therapy (CRT): Biventricular pacing. Corrects pacing-related dyssynchrony to improve functional status and reduce CCF admissions.
Mechanical Circulatory Support (MCS) & Transplantation
- Extracorporeal Membrane Oxygenation (ECMO): Temporary stabilizing measure for refractory cardiogenic shock. High morbidity demands time-limited trials with distinct end-points.
- Ventricular Assist Devices (VAD): Short or long-term mechanical support (e.g., Berlin Heart EXCOR). Utilized as a bridge to myocardial recovery or orthotopic heart transplantation.
- Orthotopic Heart Transplantation: Definitive standard of care for end-stage CCF (Stage D) or severe Stage C CCF associated with life-threatening arrhythmias, severe growth failure, or refractory symptomatology not amenable to conventional surgical repair.